November 18, 2026

Heidi Overton Faces Challenges for FDA Commissioner Nomination

Dr. Heidi Overton, nominated by President Trump for the role of FDA commissioner, is encountering obstacles in securing sufficient support in the Senate Health, Education, Labor, and Pensions Committee. The vote is set for Wednesday, but sources indicate she faces difficulty gaining enough Republican votes. No Democrats on the committee are expected to support her.

The White House reportedly acknowledges the challenge and is exploring alternative candidates for the position. This includes considering individuals who could temporarily fill the role without requiring Senate confirmation.

Overton’s nomination has been contentious due to her stance on the FDA-approved chemical abortion drug, mifepristone, and her support of pro-vaping policies during her time on the Domestic Policy Council. Senator Josh Hawley has expressed skepticism, particularly about Overton’s approach to a long-promised safety study on mifepristone. The anti-abortion group Susan B. Anthony is urging the Senate to delay Overton’s confirmation and pressuring the FDA to ban mail orders of the drug.

Republican Senators Susan Collins and Lisa Murkowski have also not committed to advancing Overton’s nomination. During the confirmation hearing, Murkowski inquired about Overton’s stance on mifepristone restrictions. The White House is discussing the possibility of an acting FDA commissioner to bypass the Senate confirmation process, given a narrow three-week legislative window ahead.

Senator Roger Marshall of Kansas, a doctor who lost his reelection bid, is reportedly interested in the FDA position. Overton is one of the notable Trump nominees facing difficulties amid waning GOP congressional control. On Tuesday, Hung Cao, nominated for Secretary of the Navy, and Eric Ueland, for the Government Accountability Office, faced their own nomination hurdles.

The FDA has been under acting Commissioner Kyle Diamantas since Marty Makary’s ousting last spring. Makary cited pressure from the White House and HHS officials regarding flavored vapes as a significant issue during his tenure.

Senator Bill Cassidy, the outgoing HELP Chairman, expressed concerns about the potential lack of a confirmed FDA commissioner. He highlighted the challenges of having a series of short-term acting administrators with potentially less independence.

Cassidy previously remarked that Overton’s connection to Trump’s efforts on reducing childhood vaccine uptake was “almost disqualifying.” Overton’s defenders point to her medical experience and endorsements from former FDA commissioners as indicators of her professionalism.

The vote for Overton, along with several other health official nominations, remains scheduled for Wednesday morning.

TAGS: